ImmunityBio, Inc. $IBRX Stock Holdings Decreased by Headlands Technologies LLC

Headlands Technologies LLC lowered its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 37.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 248,550 shares of the company’s stock after selling 148,620 shares during the quarter. Headlands Technologies LLC’s holdings in ImmunityBio were worth $2,176,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in ImmunityBio by 29.4% during the 2nd quarter. BlackRock Inc. now owns 34,083,262 shares of the company’s stock valued at $298,399,000 after purchasing an additional 7,736,819 shares during the period. Vanguard Group Inc. boosted its position in shares of ImmunityBio by 18.5% in the fourth quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company’s stock worth $64,899,000 after buying an additional 5,122,052 shares during the period. State Street Corp grew its holdings in shares of ImmunityBio by 45.4% during the fourth quarter. State Street Corp now owns 16,455,703 shares of the company’s stock valued at $32,582,000 after buying an additional 5,139,890 shares in the last quarter. Geode Capital Management LLC raised its position in ImmunityBio by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company’s stock valued at $15,684,000 after buying an additional 1,030,113 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in ImmunityBio by 439.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock valued at $12,182,000 after buying an additional 5,012,001 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

Insider Buying and Selling

In other ImmunityBio news, Director Cheryl Cohen sold 131,210 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $9.50, for a total transaction of $1,246,495.00. Following the transaction, the director directly owned 125,386 shares of the company’s stock, valued at $1,191,167. This represents a 51.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the firm’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $7.88, for a total value of $197,000.00. Following the transaction, the director owned 2,802,788 shares in the company, valued at approximately $22,085,969.44. This trade represents a 0.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 435,443 shares of company stock worth $3,918,819. Corporate insiders own 66.10% of the company’s stock.

ImmunityBio Price Performance

NASDAQ IBRX opened at $8.05 on Monday. The stock has a market capitalization of $8.53 billion, a PE ratio of -8.30 and a beta of 0.03. ImmunityBio, Inc. has a 12-month low of $1.95 and a 12-month high of $12.43. The company has a 50 day moving average price of $7.88 and a two-hundred day moving average price of $7.83.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The firm had revenue of $51.24 million for the quarter, compared to the consensus estimate of $49.70 million. As a group, equities analysts anticipate that ImmunityBio, Inc. will post -0.44 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on IBRX shares. BTIG Research reaffirmed a “buy” rating and set a $12.00 target price on shares of ImmunityBio in a research note on Thursday, May 21st. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of ImmunityBio in a report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a research report on Friday, July 10th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $23.00 price objective on shares of ImmunityBio in a research note on Tuesday, May 5th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $14.20.

ImmunityBio Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.